Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib

Linh Nguyen, Jaymes Holland, David Ramies, Richard Mamelok, Natacha Benrimoh, Sabrina Ciric, Thomas Marbury, Richard A Preston, Douglas M. Heuman, Edith Gavis, Steven Lacy

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Cabozantinib is a tyrosine kinase inhibitor approved for the treatment of patients with progressive, metastatic medullary thyroid cancer. Two clinical pharmacology studies were conducted to characterize single-dose pharmacokinetics (PK) of cabozantinib in renally or hepatically impaired subjects. Study 1 enrolled 10 subjects, each with mild or moderate impairment of renal function; 12 healthy subjects were matched to the moderate group for age, sex, and body mass index (BMI). Study 2 enrolled 8 males each with mild or moderate hepatic impairment; 10 healthy males were matched to the moderate group for age, BMI, and ethnicity. All subjects received one 60 mg cabozantinib oral capsule dose followed by PK sampling over 21 days. Plasma concentration and protein binding were determined by liquid chromatography tandem mass spectrometry and equilibrium dialysis, respectively. PK parameters were computed using noncompartmental methods. Geometric least squared mean (LSM) ratios for plasma cabozantinib AUC0-∞ for impaired to normal organ function cohorts were (1) approximately 30% and 6% higher in subjects with mild and moderate renal impairment, respectively, and (2) approximately 81% and 63% higher in subjects with mild and moderate hepatic impairment, respectively. The percentage of unbound drug was slightly higher in both moderately impaired cohorts. No deaths or discontinuations due to adverse events occurred in either study. Cabozantinib should be used with caution in subjects with mild or moderate renal impairment. Subjects with mild or moderate hepatic impairment administered cabozantinib should be monitored closely for potential treatment-emergent drug toxicity that may necessitate a dose hold or reduction.

Original languageEnglish (US)
JournalJournal of Clinical Pharmacology
DOIs
StateAccepted/In press - 2016

Fingerprint

Pharmacokinetics
Kidney
Liver
Body Mass Index
Age Groups
Clinical Pharmacology
Tandem Mass Spectrometry
Drug-Related Side Effects and Adverse Reactions
Protein Binding
Liquid Chromatography
Protein-Tyrosine Kinases
Capsules
cabozantinib
Blood Proteins
Dialysis
Healthy Volunteers
Therapeutics
Pharmaceutical Preparations

Keywords

  • Cabozantinib
  • Hepatic impairment
  • Pharmacokinetics
  • Renal impairment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Nguyen, L., Holland, J., Ramies, D., Mamelok, R., Benrimoh, N., Ciric, S., ... Lacy, S. (Accepted/In press). Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib. Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.714

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib. / Nguyen, Linh; Holland, Jaymes; Ramies, David; Mamelok, Richard; Benrimoh, Natacha; Ciric, Sabrina; Marbury, Thomas; Preston, Richard A; Heuman, Douglas M.; Gavis, Edith; Lacy, Steven.

In: Journal of Clinical Pharmacology, 2016.

Research output: Contribution to journalArticle

Nguyen, L, Holland, J, Ramies, D, Mamelok, R, Benrimoh, N, Ciric, S, Marbury, T, Preston, RA, Heuman, DM, Gavis, E & Lacy, S 2016, 'Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib', Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.714
Nguyen, Linh ; Holland, Jaymes ; Ramies, David ; Mamelok, Richard ; Benrimoh, Natacha ; Ciric, Sabrina ; Marbury, Thomas ; Preston, Richard A ; Heuman, Douglas M. ; Gavis, Edith ; Lacy, Steven. / Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib. In: Journal of Clinical Pharmacology. 2016.
@article{e67a5013eda040fa863f96f9a5f217e7,
title = "Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib",
abstract = "Cabozantinib is a tyrosine kinase inhibitor approved for the treatment of patients with progressive, metastatic medullary thyroid cancer. Two clinical pharmacology studies were conducted to characterize single-dose pharmacokinetics (PK) of cabozantinib in renally or hepatically impaired subjects. Study 1 enrolled 10 subjects, each with mild or moderate impairment of renal function; 12 healthy subjects were matched to the moderate group for age, sex, and body mass index (BMI). Study 2 enrolled 8 males each with mild or moderate hepatic impairment; 10 healthy males were matched to the moderate group for age, BMI, and ethnicity. All subjects received one 60 mg cabozantinib oral capsule dose followed by PK sampling over 21 days. Plasma concentration and protein binding were determined by liquid chromatography tandem mass spectrometry and equilibrium dialysis, respectively. PK parameters were computed using noncompartmental methods. Geometric least squared mean (LSM) ratios for plasma cabozantinib AUC0-∞ for impaired to normal organ function cohorts were (1) approximately 30{\%} and 6{\%} higher in subjects with mild and moderate renal impairment, respectively, and (2) approximately 81{\%} and 63{\%} higher in subjects with mild and moderate hepatic impairment, respectively. The percentage of unbound drug was slightly higher in both moderately impaired cohorts. No deaths or discontinuations due to adverse events occurred in either study. Cabozantinib should be used with caution in subjects with mild or moderate renal impairment. Subjects with mild or moderate hepatic impairment administered cabozantinib should be monitored closely for potential treatment-emergent drug toxicity that may necessitate a dose hold or reduction.",
keywords = "Cabozantinib, Hepatic impairment, Pharmacokinetics, Renal impairment",
author = "Linh Nguyen and Jaymes Holland and David Ramies and Richard Mamelok and Natacha Benrimoh and Sabrina Ciric and Thomas Marbury and Preston, {Richard A} and Heuman, {Douglas M.} and Edith Gavis and Steven Lacy",
year = "2016",
doi = "10.1002/jcph.714",
language = "English (US)",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib

AU - Nguyen, Linh

AU - Holland, Jaymes

AU - Ramies, David

AU - Mamelok, Richard

AU - Benrimoh, Natacha

AU - Ciric, Sabrina

AU - Marbury, Thomas

AU - Preston, Richard A

AU - Heuman, Douglas M.

AU - Gavis, Edith

AU - Lacy, Steven

PY - 2016

Y1 - 2016

N2 - Cabozantinib is a tyrosine kinase inhibitor approved for the treatment of patients with progressive, metastatic medullary thyroid cancer. Two clinical pharmacology studies were conducted to characterize single-dose pharmacokinetics (PK) of cabozantinib in renally or hepatically impaired subjects. Study 1 enrolled 10 subjects, each with mild or moderate impairment of renal function; 12 healthy subjects were matched to the moderate group for age, sex, and body mass index (BMI). Study 2 enrolled 8 males each with mild or moderate hepatic impairment; 10 healthy males were matched to the moderate group for age, BMI, and ethnicity. All subjects received one 60 mg cabozantinib oral capsule dose followed by PK sampling over 21 days. Plasma concentration and protein binding were determined by liquid chromatography tandem mass spectrometry and equilibrium dialysis, respectively. PK parameters were computed using noncompartmental methods. Geometric least squared mean (LSM) ratios for plasma cabozantinib AUC0-∞ for impaired to normal organ function cohorts were (1) approximately 30% and 6% higher in subjects with mild and moderate renal impairment, respectively, and (2) approximately 81% and 63% higher in subjects with mild and moderate hepatic impairment, respectively. The percentage of unbound drug was slightly higher in both moderately impaired cohorts. No deaths or discontinuations due to adverse events occurred in either study. Cabozantinib should be used with caution in subjects with mild or moderate renal impairment. Subjects with mild or moderate hepatic impairment administered cabozantinib should be monitored closely for potential treatment-emergent drug toxicity that may necessitate a dose hold or reduction.

AB - Cabozantinib is a tyrosine kinase inhibitor approved for the treatment of patients with progressive, metastatic medullary thyroid cancer. Two clinical pharmacology studies were conducted to characterize single-dose pharmacokinetics (PK) of cabozantinib in renally or hepatically impaired subjects. Study 1 enrolled 10 subjects, each with mild or moderate impairment of renal function; 12 healthy subjects were matched to the moderate group for age, sex, and body mass index (BMI). Study 2 enrolled 8 males each with mild or moderate hepatic impairment; 10 healthy males were matched to the moderate group for age, BMI, and ethnicity. All subjects received one 60 mg cabozantinib oral capsule dose followed by PK sampling over 21 days. Plasma concentration and protein binding were determined by liquid chromatography tandem mass spectrometry and equilibrium dialysis, respectively. PK parameters were computed using noncompartmental methods. Geometric least squared mean (LSM) ratios for plasma cabozantinib AUC0-∞ for impaired to normal organ function cohorts were (1) approximately 30% and 6% higher in subjects with mild and moderate renal impairment, respectively, and (2) approximately 81% and 63% higher in subjects with mild and moderate hepatic impairment, respectively. The percentage of unbound drug was slightly higher in both moderately impaired cohorts. No deaths or discontinuations due to adverse events occurred in either study. Cabozantinib should be used with caution in subjects with mild or moderate renal impairment. Subjects with mild or moderate hepatic impairment administered cabozantinib should be monitored closely for potential treatment-emergent drug toxicity that may necessitate a dose hold or reduction.

KW - Cabozantinib

KW - Hepatic impairment

KW - Pharmacokinetics

KW - Renal impairment

UR - http://www.scopus.com/inward/record.url?scp=84961851507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961851507&partnerID=8YFLogxK

U2 - 10.1002/jcph.714

DO - 10.1002/jcph.714

M3 - Article

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

ER -